A second blood test has been been approved by the US Food and Drug Administration to assist in diagnosing Alzheimer’s disease ...
Grail announced fresh data on Friday from a large U.S. study of its flagship Galleri blood-based test for detecting dozens of ...
The blood-based biomarker test measures Tau protein phosphorylated at threonine 181 in human plasma (pTau181).
The centerpiece of Ultra V3 is the Iris router, which replaces Jupiter’s retired Metis system. According to Jupiter Exchange, ...
The test is intended for adults 55 and older in the United States who are showing signs or symptoms of cognitive decline.
MedPage Today on MSN
New Blood Test Rules Out Alzheimer's Disease
In May, the FDA cleared the first blood-based diagnostic test for Alzheimer's disease, the Lumipulse G pTau 217/β-Amyloid ...
Eli Lilly and Company (NYSE: LLY) today announced that new data from across its oncology portfolio and pipeline will be ...
The FDA has cleared Roche's Elecsys pTau181 test, a blood-based biomarker test for Alzheimer's disease, allowing for earlier ...
Lilly to present new clinical data for Verzenio and multiple novel pipeline programMEs at the 2025 ESMO annual meeting: Indianapolis Tuesday, October 14, 2025, 09:00 Hrs [IST] Eli ...
AI’s real power lies not only in logistics efficiency but also in building long-term relationships with customers. Their ...
This comes at the heel of FDA's nod for Fujirebio Diagnostics' blood test Lumipulse in May, the first such device to get ...
More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback